Turin

• A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised
  2022-502126-40-00 5 HIV-1 infection
• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d … Not authorised
  2022-502185-24-00 5 Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
• MK-0616-013 Not authorised
  2022-502777-42-00 5 Hypercholesterolemia
• MELFLUFEN FOR ELDERLY PATIENTS WITH RELAPSED MYELOMA Not authorised
  2024-514652-33-00 4 Relapsed Multiple Myeloma
• A multicentre randomised study on percutaneous stellate ganglion block as first-line treatment in patients with electrical storm: the STAR 2 … Not authorised
  2024-520387-34-00 6 electrical storm
• A one-year study to assess if Xanomeline/Trospium (XT) can improve cognitive function in adults living with schizophrenia. Not authorised
  2025-523060-20-00 5 Schizophrenia
• Clinical and ultrasound assessment of the therapeutic response to ixekizumab in psoriatic arthritis dactlylitis; a multicentre, parallel-gro … Pending
  2022-503119-40-00 5 psoriatic arthritis (PsA)
• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 4 prostate cancer
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed Pending
  2024-511054-50-00 10 HIV-1 Infection
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• The impact of PDD during TURB for NMIBC: a prospective randomized controlled trial Pending
  2024-514316-27-00 6 Not muscular invasive bladder cancer
• PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending
  2024-514355-16-01 5 Acute Respiratory Distress Syndrome (ARDS)
• A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending
  2024-514701-57-01 4 non Small Cell Lung Cancer
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Pending
  2024-516436-10-00 5 Acute myeloid leukemia
• Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystec … Pending
  2024-516943-14-01 4 Muscle-Invasive Bladder cancer
• A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resec … Pending
  2024-517565-16-00 4 Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma
• IMpAct of CardiolRxTM oVer 6 months following IL-1 Blocker cessation in pERICarditis patients – MAVERIC: A randomized, double-blind, placebo … Pending
  2024-517688-21-00 5 Recurrent Pericarditis
• Use of Sulodexide (VESSEL®) for the prevention of a new episode in elderly patients who have had a first episode of deep vein thrombosis and … Pending
  2024-517796-21-00 5 Prevention of recurrence after a first episode of Venous Thromboemboli
• A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY … Pending
  2024-517861-18-00 5 Idiopathic IgA nephropathy (IgAN)
• Single-blinded randomized investigator-initiated controlled trial to assess the efficacy of colchicine to treat patients with cardiomyopathy … Pending
  2024-517945-14-00 5 Inflammatory cardiomyopathy
• Double-blind randomized controlled study versus placebo to evaluate the efficacy of mono-administration of betamethasone in children with sy … Pending
  2024-518095-31-00 5 Adenovirus infection
• Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial) Pending
  2024-518388-37-00 4 Intermediate risk prostate cancer

Showing 1–24 of 632 trials